19 June
Here is our weekly roundup on the latest research and scientific efforts against the coronavirus.
Sanofi
Sanofi is investing more than half a billion euros to increase its vaccine research and production capacities. This investment will see the development of a vaccine production site in Neuville sur Saône, France, and a new vaccine research centre in Marcy-l’Etoile, France. These facilities will provide innovative technologies to equip Sanofi with the readiness and flexibility to respond to future pandemic risks.
Read more here.
Imperial College London
Following successful laboratory tests, Imperial College London will proceed with human testing of a covid-19 vaccine developed by the University’s researchers.
Read more here.
Eli Lilly
Lilly has begun to enrol 400 participants for a phase 3 study of its JAK inhibitor baricitinib, marketed as OLUMIANT®. The study will take place in the US, Europe and Latin America, testing patients hospitalised with covid-19 and who have at least one elevated marker of inflammation.
Read more here.
Johnson & Johnson
Johnson & Johnson has announced it will bring forward the human testing trial of its covid-19 vaccine candidate to July. The placebo-controlled phase 1/2a trial of the adenovirus-based candidate, known as Ad26.COV2-S, taking place in the US and Belgium, will involve two groups of adults, one aged 18 to 55 and another aged 65 and older.
Read more here.
Gilead Sciences
Gilead Sciences is set to begin trials of its antiviral drug remdesivir in children with covid-19. The phase 2/3 trail will involve around 50 subjects – from new-borns to adolescents, at more than 30 sites across the US and Europe. The trial is expected to be completed in December of this year.
Read more here.
Keep up to date on the response from the chemical industry and the scientific community to the COVID-19 (coronavirus) outbreak. SCI will be covering key coronavirus research and reporting news from trusted sources so that you have the coronavirus latest.
Visit Blog